Increase dosage gradually
Ideal for those seeking a caffeine-balanced, natural solution to manage appetite, support mood, and boost overall metabolism
In the meantime, this study reminds us that the doseresponse curve of incretin therapies is never just quantitative, but also qualitative: new doses can bring not only more efficacy, but also entirely new clinical scenarios in terms of safety
Exploring the Potential of MSC Therapy in Cardiovascular Health: What Patients Should Know June 25, 2025 A New Frontier in Cardiovascular Health Cardiovascular disease remains the leading cause of death in the United States, with atherosclerosischaracterized by plaque buildup in the arteriesplaying a central role
Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment
What research has been published on Retatrutide